TRX Announces Positive Trials for Oral Small Molecule Amylin and GLP-1 Programs
Structure Therapeutics reported positive Phase 1/2a SAD data for its amylin agonist ACCG-2671 and 72-week OLE data for GLP-1 agonist aleniglipron, showing weight loss without plateau. The company also initiated Phase 3 trials and confirmed upcoming data visibility.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day